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Original Article 
Mitosis count and number of cancer cells in cases of primary pulmonary 
adenocarcinoma – correlations among phosphorylated histone 3, number of 
cancer cells, nuclear grade, pathologic features and prognosis 
 
Running title: Mitosis count in lung adenocarcinoma 
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Abstract 
Immunohistochemistry findings for the phosphorylated form of histone 3 
(pHH3) have been shown to be a reliable mitosis-specific marker. We 
evaluated the correlation between pHH3-stained mitotic figures (PHMFs) 
and clinical outcome, and compared the results with findings for numbers of 
PHMFs and cancer cells. The primary tumor was obtained from 113 
patients with pulmonary adenocarcinomas (≤2 cm maximum dimension). All 
specimens were stained with pHH3, then the number of cancer cells in each 
was determined. Cases with a cancer-cell index ≥1000 showed worse 
recurrence-free survival as compared to those with a value <1000 (p<0.001). 
Also, cases with a pHH3 index ≥0.27 showed worse recurrence-free survival 
as compared to <0.27 (p=0.001) and cases with a pHH3/cancer-cell index 
≥0.001 showed worse recurrence-free survival as compared to <0.001 
(p=0.002). Multivariate analysis demonstrated that pHH3/cancer-cell index 
was significantly correlated with prognosis, but not Ki-67 index. The 
number of cancer cells was also strongly correlated with progression of 
Noguchi’s classification and WHO pathologic type. pHH3/cancer-cell index 
was correlated with prognosis, and those were useful for prognostic 
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evaluation of pulmonary adenocarcinoma patients. Furthermore, cancer cell 
number was correlated with Noguchi’s classification and WHO pathologic 
type. 
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histological classification, phosphorylated histone 3 
 
  4 
Introduction 
Based on histology findings, adenocarcinoma is the most frequent type 
of lung cancer encountered in most countries.1 Histological grading of lung 
cancer is a significant indicator of prognosis, with several prognostic factors 
shown to correlate with patient outcome. In addition, increasing evidence 
suggests that lung adenocarcinoma morphologic characteristics, such as 
architectural and nuclear features, can stratify patients in regard to 
prognosis.2–10 The newly proposed International Association for the Study of 
Lung Cancer (IASLC)/American Thoracic Society (ATS)/European 
Respiratory Society (ERS) International Multidisciplinary Classification of 
Lung Adenocarcinoma clearly emphasizes the prognostic significance of 
histologic subtypes in lung adenocarcinoma,11 which has been validated by 
use of independent datasets.12 Furthermore, to define comprehensive 
pathological prognostic marker sets, interest in the prognostic value of 
pathologic characteristics other than architecture is increasing. For example, 
evidences showing that mitotic count13, 14 and Ki-67 labeling15 are useful for 
predicting recurrence of stage I adenocarcinoma have been presented, as 
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well as findings indicating that nuclear area and major dimension are 
independent prognostic markers.9 
Recently presented immunohistochemistry (IHC) results for 
phosphorylated histone 3 (pHH3), which is present during early prophase, 
have shown it to be a reliable mitosis-specific marker.16, 17 pHH3 has also 
been found useful for assessment of proliferation index in gliomas,18 
meningiomas,19 melanomas,20 uterine smooth muscle tumors,21 and pulmo-
nary neuroendocrine carcinomas,22 as well as to decrease inter-observer 
variability for detection of mitosis in melanomas.20 pHH3 should be 
interpreted as positive only in cells with a staining pattern that highlights a 
mitotic figure. 
Thus far, no study has been presented showing a correlation between 
pHH3-stained mitotic figures (PHMFs) and survival in patients with a 
pulmonary adenocarcinoma. In this study, we evaluated the correlation 
between PHMFs and clinical outcome, and compared the results with those 
for hematoxylin and eosin mitotic figures (HEMFs) and Ki-67 labeling 
index. 
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There are also no known studies regarding the correlation between 
number of cancer cells in a tumor and prognosis. Here, we counted the 
number of cancer cells in tumors and calculated tumor size, by which the 
number of cancer cells /mm2 was calculated. We then evaluated the 
correlation of number of cancer cells with WHO classification, Noguchi’s 
classification, and patient prognosis. 
 
Material and methods 
Patients 
Primary tumors were obtained from consecutive 113 patients with 
pulmonary adenocarcinomas (2 cm maximum dimension) who were treated 
surgically during the period between January 2006 and December 2010. All 
patients underwent surgical resection at Dokkyo Medical University 
Hospital, Tochigi, Japan and informed consent for using materials for the 
study was obtained from each. Dokkyo Medical University Hospital Ethical 
Committee approved this study (#28147). Follow-up examinations were 
completed for all patients by September 2017. 
 
  7 
Tissue specimens and pathologic information 
Resected specimens were fixed in 10% to 15% neutral buffered formalin 
at room temperature, then embedded in paraffin for histology examinations. 
Sections (2 μm thick), including the largest cut surface of the tumor, were 
made, then stained with hematoxylin and eosin (H&E), and examined under 
light microscopy. Tumors were classified according to the criteria of the 
WHO International Histological classification of Tumours23 as well as 
histological criteria proposed by Noguchi and colleague24, which classified 
small-sized lung adenocarcinomas histologically. Staging was evaluated 
according to the International Union Against Cancer TNM Classification of 
Malignant Tumors (seventh edition)25. 
 
Immunohistochemical examinations 
After all H&E-stained slides were reviewed, 1 representative block 
from each case was selected. Next, 4-μm sections were cut from the selected 
blocks, then deparaffinized in xylene and dehydrated in graded alcohol 
solutions. A standard avidin–biotin complex peroxidase technique was used 
for immunohistochemical staining of primary antibodies against pHH3 
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(Ser10, polyclonal, dilution 1:2000) and an anti-Ki-67 antibody (clone MIB-1, 
Immunotech, Westbrook, ME; dilution 1:100). For immunohistochemical 
staining, 4-μm-thick sections were deparaffinized. Heat-induced epitope 
retrieval was performed using Target Retrieval Solution High pH (DAKO, 
Carpenteria, CA) for pHH3 and Target Retrieval Solution (DAKO) for Ki-67. 
The sections were then stained using a Ventana Discovery XT automated 
immunohistochemical staining device (Ventana, Tucson, AZ), according to 
the manufacturer’s guidelines. Diaminobenzidine was used as the 
chromogen and hematoxylin as the nuclear counterstain.  
 
Histologic evaluations and nuclear grading criteria 
Mitoses were counted using 1 representative H&E- and pHH3-stained 
slide for each case under an Olympus BX53 microscope (Olympus, Tokyo, 
Japan). In this manner, the number of mitoses in each tumor specimen was 
determined. We also counted the number of cancer cells in the tumor 
specimens using a NanoZoomer® Digital Pathology device (Hamamatsu 
Photonics, Japan). All counts were performed by viewing the monitor screen 
with a ×40 objective and ×10 video ocular. When examining the fields, all 
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tumor cells were selected, while necrotic and inflammatory areas were 
avoided, though overlapping nuclei were omitted. The nuclear profile 
measurement area was assessed by tracing the nuclear membrane with the 
computer mouse (Figure 1 a). We also count square-meter of tumor by this 
virtual slide system (Figure 1 b).  
We also determined the Ki-67 index of 1000 of the counted tumor 
nuclei, which was expressed as the percentage of Ki-67-positive nuclei as 
compared with all counted tumor nuclei. 
We previously reported that the nuclear grading system is a useful 
parameter for determining the prognosis of patients with small pulmonary 
adenocarcinomas.9 In this study, we chose fields where large nuclei were 
frequently observed in the largest cut surface of each tumor. Necrotic and 
inflammatory areas were avoided, and overlapping nuclei were omitted. Any 
tumor cell was judged to be positive when its nuclear area and nuclear 
dimension were 5 and 3 times larger, respectively, than the corresponding 
values for small lymphocytes (figure 2). Trained observers (I.Y, K.M, and 
K.H) reviewed each slide in detail using low magnification (×40) and 
selected a few areas that included tumor cells with large nuclei. The number 
  10 
of tumor cells judged to be positive was then counted and a field was judged 
as a positive field if it contained more than 5 positive cells. The case was 
judged as a positive case when more than 3 such positive fields were 
observed. 
 
Statistical analysis 
Associations between clinicopathologic variables and histologic findings 
were analyzed using Fisher’s exact test for categorical variables and 
Wilcoxon’s test for continuous variables. Analyses of the correlations of 
clinicopathologic features with nuclear size and pHH3 mitosis were 
performed using an F test, Student’s t test, and Tukey’s test. Receiver 
operating characteristic (ROC) curve analysis was done to estimate an 
optimal cutoff level of each variable. Patients were followed from the time of 
surgery to documented recurrence, and censored on the date of death or last 
follow-up if no recurrence was noted. Data for patients lost to follow-up were 
also censored. Overall survival (OS) and recurrence-free survival (RFS) 
curves were calculated using the Kaplan-Meier method and non-parametric 
group comparisons were performed using a log-rank test. Multivariate 
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analyses were performed using Cox proportional hazards regression. 
Relationships among the number of HEMFs, PHMFs, and Ki-67 index were 
investigated using Pearson’s correlation coefficient test. A p value less than 
0.05 was regarded as significant. We examined features shown to be 
significant in univariate analysis findings using a multivariate model. 
Independent staging factors for pulmonary adenocarcinomas were evaluated 
by multivariate analysis for nuclear grading. All analyses were performed 
using the SPSS statistical software package (version 23.0; SPSS, Chicago, 
IL, USA, 2016). 
 
Results 
Clinical findings 
The clinicopathologic features of the cases examined are listed in Table 
1. Mean observation periods were both 5.7 years, ranged from 0.5 to 9.1 
years. The clinicopathologic features of the recurrence cases examined are 
listed in Supplementary Table 1.  
 
Correlation between nuclear grade and prognosis 
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Kaplan-Meier survival curve analysis showed that the mean RFS of 
patients whose nuclear grade was positive was 8.6 years (95% confidence 
interval(CI), 7.62 - 9.50 ), while that of those with nuclear grade negative 
findings was 10.8 years (95% CI,10.6 - 11.6 ). Thus, a nuclear grade positive 
finding was significantly correlated with recurrence (p<0.01) (Figure 3 a). 
Also Kaplan-Meier survival curve analysis showed that the mean OS of 
patients whose nuclear grade was positive was 7.3 years (95% CI, 6.66 - 
7.94), while that of those with nuclear grade negative findings was 8.4 years 
(95% CI, 7.84 - 9.04). Thus, a nuclear grade positive finding was 
significantly correlated with shorter survival (p=0.037) (Supplementary 
Figure 1 a). 
 
Correlation between cancer cell index and prognosis 
We counted the number of pHH3-positive cells among all cancer cells 
in a total of 113 slides (Figure 1). The mean number of pHH3-positive cells 
per slide was 32.8 (range 0 to 234).  
In small-sized adenocarcinomas, there were few positive cells, thus we 
analyzed all tumor cells in whole specimens and found that number of 
cancer cells ranged from 3670 to 178,568 per tumor, with an average of 
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67,605 (Figure 2). We defined cancer cell index as the number of cancer cells 
within 1 mm2. ROC curve analysis showed a cut-off value of 992 /mm2 (area 
under the curve (AUC)=0.697, 95%CI=0.576-0.817). In general, cases with a 
cancer cell index of ≥1000 had worse RFS as compared to those with a value 
<1000 (mean RFS 5.42 years, 95% CI 3.80 - 7.04vs. 10.6 years, 95% CI 10.1 - 
11. 2, p<0.001) (Figure 3 b). Also cases with a cancer cell index of ≥1000 had 
worse OS as compared to those with a value <1000 (mean OS 5.95 years, 
95% CI 4.75 - 7.15vs. 8.14 years, 95% CI 7.72 - 8.65, p<0.001) 
(Supplementary Figure 1 b).  
 
Correlation between pHH3/cancer cell index and prognosis 
We defined pHH3 index as the number of pHH3 positive cells within 1 
mm2. ROC curve analysis revealed a cut-off value of 0.27 /mm2 (AUC=0.725, 
95%CI=0.595-0.855). Cases with a pHH3 index of ≥0.27 had worse RFS as 
compared to those with a value <0.27 (mean RFS 7.73 years, 95% CI 6.64 - 
8.81 vs. 10.8 years, 95% CI 10.3 - 11.4, p<0.001) (Figure 3 c). Also cases with 
a pHH3 index of ≥0.27 had worse OS as compared to those with a value 
<0.27 (mean OS 6.95 years, 95% CI 6.92 - 7.70 vs. 8.46 years, 95% CI 7.95 - 
8.97, p=0.001) (Supplementary Figure 1 c). 
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We then defined the cut-off number for pHH3 positive cells/cancer cells 
as the pHH3/cancer cell index. ROC curve analysis revealed a cut-off value 
of 0.00092 (AUC=0.661, 95%CI=0.531-0.792). Cases with a pHH3/cancer cell 
index of ≥0.001 had worse RFS as compared to those with a value <0.001 
(mean RFS 5.86 years, 95% CI 3.77 - 7.96 vs. 9.92 years, 95% CI 9.24 - 10.6, 
p<0.001) (Figure 3 d). Also cases with a pHH3/cancer cell index of ≥0.001 
had worse OS as compared to those with a value <0.001 (mean OS 5.74 
years, 95% CI 4.29 - 7.19 vs. 7.97 years, 95% CI 7.49 - 8.45, p=0.002) 
(Supplementary Figure 1 d). 
Furthermore, ROC curve analysis of Ki-67 index revealed a cut-off 
value of 11.3 (AUC=0.676, 95%CI=0.566-0.786). Cases with a Ki-67 index of 
≥11.3 had worse RFS as compared to those with a value <11.3 (mean RFS 
7.97 years, 95% CI 6.66- 9.29 vs. 10.3 years, 95% CI 9.61-11.03, p=0.005) 
(Figure 3 e). Also Cases with a Ki-67 index of ≥11.3 had worse OS as 
compared to those with a value <11.3 (mean OS 7.15 years, 95% CI 6.33 - 
7.97 vs. 8.08 years, 95% CI 7.52- 8.63, p<0.001) (Supplementary Figure 1 e). 
 
Correlations between pHH3/cancer cell index and Noguchi's classification or 
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WHO classification 
Univariate analysis demonstrated that pHH3/cancer cell index, cancer 
cell index, pHH3 index, Ki-67 index, nuclear grade, WHO classification, 
pathological stage, lymphatic invasion and vascular invasion were strongly 
correlated with patient RFS (p<0.05) (Table 2). Also univariate analysis 
demonstrated that pHH3/cancer cell index, cancer cell index, pHH3 index, 
nuclear grade, WHO classification, pathological stage and lymphatic 
invasion were strongly correlated with patient OS (p<0.05) (Supplementary 
Table 2). 
Multivariate analysis demonstrated that pHH3/cancer cell index was 
strongly correlated with patient RFS (p<0.05). Furthermore, Cox regression 
analysis showed that pHH3/cancer cell index had a hazard ratio of 3.505 
(p=0.008) (Table 2). Also multivariate analysis demonstrated that 
pHH3/cancer cell index and WHO classification were strongly correlated 
with patient OS (p<0.05). Furthermore, Cox regression analysis showed that 
pHH3/cancer cell index had a hazard ratio of 2.445 (p=0.048) 
(Supplementary Table 2). 
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We analyzed the correlation between number of cancer cells and 
Noguchi’s classification, and noted a greater number of cancer cells as the 
classification increased (Figure 4 a). We divided the patients into the 
Noguch-1 group, which was composed of those classified as Noguchi A and B, 
and Noguchi-2, composed of Noguchi C, D, E, and F patients. Cancer cell 
index showed a strong correlation with this grouping (average: 537.6/mm2 in 
Noguchi-1, 848.0/mm2 in Noguchi-2, P<0.05). We also analyzed the 
correlation between number of cancer cells and WHO classification, and 
found that the classification became worse with a greater number of cancer 
cells (Figure 4 b). In addition, we divided patients based on WHO 
classification into 2 groups, those with an adenocarcinoma in situ or 
minimally invasive adenocarcinoma (WHO-1), and cases of invasive 
carcinoma including lepidic, papillary, acinar, and solid predominant 
adenocarcinomas (WHO-2). Our results showed that cancer cell index was 
strongly correlated with this grouping (average: WHO-1, 620.7/mm2; WHO-2, 
872.8/mm2; p<0.05) 
 
Discussion 
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In this curated series of resected pulmonary adenocarcinoma cases, 
pHH3/cancer cell index were independent prognostic factors related to OS 
and RFS. If prospectively validated, our results may have important 
implications for adjuvant management and follow-up of patients undergoing 
resection of lung adenocarcinoma. 
Mitotic figures are indicators of tumor proliferation ability, with higher 
growth rate related to higher grade of malignancy and elevated risk of 
recurrence. Histopathologically, assessment of mitotic figures is important 
and performed for patients with a variety of diseases. In cases of 
astrocytoma, WHO recommends that mitotic count is useful for pathological 
grading.26 Similarly, mitotic count is important for gastrointestinal stromal 
tumor cases27 and it has been pointed out that it correlates with recurrence 
and patient prognosis.  
Mitotic count for lung cancer has been examined in several studies. 
Ki-67 labeling index was found to be a statistically significant prognostic 
factor for disease-free survival of patients with non-small cell lung cancer 
who underwent a video-assisted thoracoscopic segmentectomy procedure.15 
Also, Kadota et al. demonstrated a significant association of mitotic count 
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with histology grade, Ki-67 proliferative index, and recurrence-free 
probability, and concluded that mitotic count was the single most important 
predictor of recurrence in patients with stage 1 lung adenocarcinoma.14 In 
another study, Duhig et al. suggested that mitotic index is the only 
independent prognostic marker for patients who have undergone resection 
for stage I lung adenocarcinoma.28 
In our study, we counted mitotic figures using the pHH3 stain. 
Recently, immunohistochemistry findings for pHH3, which is present during 
early prophase, have shown it to be a reliable mitosis-specific marker16, 17 
and also useful for assessment of proliferation index in gliomas,18 
meningiomas,19 melanomas,20 and uterine smooth muscle tumors,21 with 
decreased inter-observer variability for detecting mitosis in melanomas.20 
pHH3 should be interpreted as positive only in cells with a staining pattern 
that highlights a mitotic figure. Counting mitotic figures with the assistance 
of pHH3 immunostaining is more sensitive for detecting mitotic figures than 
the traditional method of counting H&E-stained mitotic figures, which was 
reported by Tsuta et al. regarding lung neuroendocrine tumors.22 In the 
present study, pHH3 index was strongly correlated with patient prognosis, 
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as those with a value ≥0.27 had worse OS as compared to those with a value 
<0.27 (5-year survival 69.5% vs. 92.7%, p=0.001). In the present study, we 
counted the number of cancer cells in individual tumor specimens. Although 
there are no previous reports regarding the number of cancer cells in lung 
adenocarcinoma tumors, we considered that a higher number of cancer cells 
would be associated with worse prognosis, thus cancer cell index would also 
be strongly correlated with prognosis. Our results showed that patients with 
a cancer cell index ≥1000 had worse OS as compared to those with an index 
<1000 (5-year survival 52.5% vs. 89.3%, p<0.001). Also, in analysis of the 
correlation between number of cancer cells and Noguchi’s classification, the 
classification increased as the number of cancer cells increased. After 
dividing our patients into two groups based on Noguchi’s classification 
(Noguchi-1: Noguchi A, B; Noguchi-2: Noguchi C, D, E, F), cancer cell index 
was shown to be strongly correlated with that grouping (average: Noguchi-1, 
537.6/mm2; Noguchi-2, 848.0/mm2; P<0.05). We also analyzed the correlation 
between number of cancer cells and WHO classification, which revealed that 
the classification worsened as the number of cancer cells increased. 
Following division of our patients into two groups based on WHO 
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classification (WHO-1: adenocarcinoma in situ, minimally invasive 
adenocarcinoma; WHO-2: invasive carcinoma including lepidic, papillary, 
acinar, solid predominant adenocarcinomas), cancer cell index was strongly 
correlated with this grouping (average: WHO-1, 620.7/mm2; WHO-2, 
872.8/mm2; p<0.05). 
We analyzed the pHH3/cancer cell index in the present study and 
found a strong relationship between it and OS (log-rank test, P=0.048). 
Thus, when the ratio of pHH3-positive cells to cancer cells is greater than 
1:1000, patient prognosis is poor. In addition, multivariate analysis showed 
that high pHH3/cancer cell index was significant risk factors for death.  
In conclusion, our findings stress the importance of pHH3/cancer cell 
index for estimating malignancy of small-sized adenocarcinomas in the lung. 
Application of pHH3/cancer cell index along with a pure histological 
classification such as the WHO or Noguchi classification may make more 
precise prediction of the biological behavior of small-sized adenocarcinomas 
as compared to histological classification. 
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Figure Legends 
 
Figure 1. Histology findings of small adenocarcinoma.  
We counted the number of cancer cells (yellow-lined nucleus) in each tumor 
specimen using a NanoZoomer® Digital Pathology device (Hamamatsu 
Photonics, Japan). 
 
Figure 2. Histological findings of representative small pulmonary 
adenocarcinomas judged to be nuclear grade positive (a, b, c) or nuclear 
grade negative (d, e, f).  
a) Hematoxylin and eosin stain, original magnification ×200. Solid-type 
adenocarcinoma with nuclear grade positive cells. 
b) Ki-67 staining of tumor shown in 1-a, original magnification ×200. A 
large number of Ki-67-positive cells can be seen. 
c) PHH3 staining of tumor shown in 1-a, original magnification ×200. 
Three pHH3-positive cells can be seen. 
d) Hematoxylin and eosin stain, original magnification ×100. Lepidic-type 
adenocarcinoma with nuclear grade negative cells. 
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e) Ki-67 staining of tumor shown in 1-d, original magnification ×100. Only 
a few Ki-67-positive cells can be seen. 
f) PHH3 staining of tumor shown in 1-d, original magnification ×100. One 
pHH3-positive cell can be seen. 
 
Figure 3. Recurrence-free survival curves for all patients. 
(a) Recurrence-free survival curves for patients with nuclear grade positive 
and negative (p<0.01). (b) A cancer cell index (number of cancer cells/mm2) 
value of 1000 was used as the cutoff (p<0.001). (c) A pHH3 index (number of 
pHH3 cells/mm2) value of 0.27 was used as the cutoff (p<0.001). (d) A 
pHH3/cancer cell index (number of pHH3 positive cells among all cancer 
cells) value of 0.001 was used as the cutoff (p<0.001). (e) A Ki-67 index value 
of 0.125 was used as the cutoff (p=0.005). 
 
Figure 4. Box plot of cancer cells in all patients classified according to (a) 
Noguchi’s and (b) WHO pathologic classification. 
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Supplementary Figures Legends 
 
Supplementary Figure 1. Overall survival curves for all patients. 
(a) Overall survival curves for patients with nuclear grade positive and 
negative (p=0.037). (b) A cancer cell index (number of cancer cells/mm2) 
value of 1000 was used as the cutoff (p<0.001). (c) A pHH3 index (number of 
pHH3 cells/mm2) value of 0.27 was used as the cutoff (p=0.001). (d) A 
pHH3/cancer cell index (number of pHH3 positive cells among all cancer 
cells) value of 0.001 was used as the cutoff (p=0.002). (e) A Ki-67 index value 
of 0.125 was used as the cutoff (p<0.001). 
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Supplementary Table Legends 
 
Supplementary Table 1. Recurrent patients characteristics 
Supplementary Table 2. Cox regression analysis findings of overall survival 
 
 
